Use of viral resistance patterns to antiretroviral drugs in optimising selection of drug combinations and sequences

Drugs

Volumn 52, Issue 2, 1996, Pages 168-185

  Moyle, Graeme J ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

CROSS RESISTANCE; DEATH; DISEASE COURSE; DRUG EFFECT; DRUG SENSITIVITY; DRUG TOXICITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PATIENT CARE; PHENOTYPE; REVIEW; TREATMENT PLANNING; VIRUS MUTANT; VIRUS REPLICATION; VIRUS RESISTANCE;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0029774808     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199652020-00002     Document Type: Review

References (159)

1. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373: 117-22
2. Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373: 123-6
3. Mansky LM, Temin HM. Lower in vivo mutation rate of human immunodeficiency virus type 1 than predicted from fidelity of purified reverse transcriptase. J Virol 1995; 69: 5087-94
4. Schinazi RF, Lloyd RM, Ramanathan CS, et al. Antiviral drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase occur in specific RNA structural regions. Antimicrob Agents Chemother 1994; 38: 268-74
5. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis and therapy. Science 1995; 267: 483-9
6. Haseltine WA, Wong-Staal F. The molecular biology of the AIDS virus. Sci Am 1989; 259: 34-42
7. Saag MS, Hahn BA, Gibbons J, et al. Extensive variation of human immunodeficiency virus type 1 in vivo. Nature 1988; 334: 440-4
8. Kunzi MS, Groopman JE. Identification of a novel human immunodeficiency virus strain cytopathic to megakaryocytic cells. Blood 1993; 81: 3336-42
9. Connor RI, Ho DD. Human immunodeficiency virus type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression. J Virol 1994; 68: 4400-8
10. Mohri H, Singh MK, Ching WTW, et al. Quantitation of zidovudine-resistant human immunodeficiency virus type 1 in the blood of treated and untreated patients. Proc Natl Acad Sci USA 1993; 90: 25-9
11. Nájera I, Richman DD, Olivares I, et al. Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates. AIDS Res Hum Retroviruses 1994; 10: 1479-88
12. Nájera I, Holguín A, Quiñones-Mateu E, et al. Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J Virol 1995; 69: 23-31
13. Frost SDW, McLean AR. Quasispecies dynamics and the emergence of drug resistance during zidovudine therapy of HIV infection. AIDS 1994; 8: 323-32
14. Kellam P, Boucher CAB, Tijnagal JMGH, et al. Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance. J Gen Virol 1994; 75: 341-51
15. Chow YK, Hirsch MS, Merrill DP, et al. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy. Nature 1993; 361: 650-3
16. Coffin JM. Genetic diversity and evaluation of retroviruses. Curr Top Microbiol Immunol 1992; 176: 143-64
17. Boucher CAB, O'Sullivan E, Mulder JW, et al. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis 1992; 165: 105-10
18. Condra JH, Schleif WA, Blahy OM, et al. Dynamics of acquired HIV-1 clinical resistance to the protease inhibitor MK-639 [abstract no. 72]. 4th International HIV Drug Resistance-Workshop: 1995 Jul 6-9; Sardinia
19. Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995; 374: 569-71
20. Rooke R, Tremblay M, Soudeyns H, et al. Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy. AIDS 1989; 3: 411-5
21. Albert J, Wahlberg J, Lundeberg J, et al. Persistence of azidothymidine-resistant human immunodeficiency virus type 1 RNA genotypes in post-treatment sera. J Virol 1992; 66: 5627-30
22. Condra JH, Schleif WA, Blahy OM, et al. Evidence for the existence of long-lived genetic reservoirs of HIV-1 in infected patients [abstract no. 82], 4th International HIV Drug Resistance Workshop: 1995 Jul 6-9; Sardinia
23. Larder BA, Darhy G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy Science 1989; 243: 1731-4
24. Smith MS, Koerher KL, Pagano JS. Long-term persistence of zidovudine resistance mutations in plasma isolates of human immunodeficiency virus type 1 of dideoxyinosine-treated patients removed from zidovudine therapy. J Infect Dis 1994; 169: 184-8
25. Boucher CAB, Termette M, Lange JMA, et al. Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy. Lancet 1990; 336: 585-90
26. Lopez-Galindez C, Rojas JM, Nájeru R, et al. Characterization of genetic variation and AZT resistance mutations of HIV by the RNAse mismatch cleavage method. Proc Natl Acad Sci USA 1991; 88: 4280-4
27. Larder BA, Kellam P, Kemp SD. Zidovudine resistance predicted by direct detection of mutants in DNA from HIV-infected lymphocytes. AIDS 1991; 5: 137-44
28. De Jong MD, Veenstra J, Stilianakis N, et al. Return to baseline values of HIV-1 RNA load during zidovudine treatment is associated with the emergence of K70R mutant virus [abstract no. 20]. 4th International HIV Drug Resistance Workshop: 1995 Jul 6-9; Sardinia
29. Mayers DL, McCutchan FE, Sanders-Buell EE, et al. Characterization of HIV isolates arising after prolonged zidovudine therapy. J Acquired Immune Defic Syndr 1992; 5: 749-59
30. St Clair MH, Martin JL, Tudor-Williams G, et al. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991; 253: 1557-9
31. Eron JJ, Chow YK, Caliendo AM, et al. Pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo. Antimicrob Agents Chemother 1993; 37: 1480-7
32. Larder BA. 3′Azido-3′deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 1992; 36: 2664-9
33. Boucher CAB, Cammack N, Schipper P, et al. High-level resistance to (-)enantiomeric 2′-deoxy-3′-thiacytidine (3TC) in vitro is due to one amino acid substitution in the catalytic site of HIV-1 reverse transcriptase. Antimicrob Agents Chemother 1993; 37: 2231-4
34. Tisdale M, Kemp SD, Parry NR, et al. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 1993; 90: 5633-56
35. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995; 269: 696-9
36. Zhang D, Caliendo AM, Eron JJ, et al. Resistance to 2′,3′-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1994; 38: 282-7
37. Richman DD, Guatelli JC, Grimes J, et al. Detection of mutations associated with zidovudine resistance in human immunodeficiency virus by use of the polymerase chain reaction. J Infect Dis 1991; 164: 1075-81
38. Lacey SF, Larder BA. Mutagenic study of codons 74 and 215 of the human immunodeficiency virus type 1 reverse transcriptase, which are significant in nucleoside analog resistance. J Virol 1994; 68: 3421-4
39. Larder BA, Chesebro B, Richman DD. Susceptibilities of zidovudine-susceptible and resistant human immunodeficiency virus isolales to antiviral agents determined by using a quantitative plaque reduction assay. Antimicrob Agents Chemother 1990; 34: 436-41
40. Rooke R, Parniak MA, Tremblay M, et al. Biological comparisons of wild-type and zidovudine-resistant isolates of human immunodeficiency virus type 1 from the same subjects: susceptibility and resistance to other drugs. Antimicrob Agents Chemother 1991; 35: 988-91
41. Lin P-F, Samanta H, Rose RK, et al. Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy. J Infect Dis 1994; 170: 1157-64
42. Dimitrov DH, Hollinger FB, Baker CJ, et al. Study of human immunodeficiency virus resistance to 2′3′-dideoxyinosine and zidovudine in sequential isolates from pediatric patients on long-term therapy. J Infect Dis 1993; 167: 818-23
43. Japour AJ, Chatis PA, Eigenrauch HA, et al. Detection of human immunodeficiency virus type 1 clinical isolates with reduced sensitivity to zidovudine and dideoxyinosine by RNA-RNA hybridization. Proc Natl Acad Sci USA 1991; 88: 3092-6
44. Mayers DL, Japour AJ, Arduino J-M, et al. Dideoxynucleoside resistance emerges with prolonged zidovudine therapy. Antimicrob Agents Chemother 1994; 38: 307-14
45. Richman DD, Grimes JM, Lagakos SW. Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. J Acquired Immune Defic Syndr 1990; 3: 743-6
46. Japour AJ, Welles S, D'Aquila RT, et al. Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. J Infect Dis 1995; 171: 1172-9
47. Shirasaka T, Yarchoan R, Husson S, et al. HIV may develop resistance preferentially to azidothymidine (AZT) as compared to dideoxycytidine (ddC) and dideoxyinosine (ddI) in patients receiving antiviral therapy. VIIth International Conference on AIDS: 1991 Jun 16-21; Florence
48. Richman DD. Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob Agents Chemother 1993; 37: 1207-3
49. Shirasaka T, Yarchoan R, O'Brien MC, et al. Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine and dideoxyinosine: an in vitro comparative study. Proc Natl Acad Sci USA 1993; 90: 562-6
50. Richman DD, Meng TC, Spector SA, et al. Resistance to AZT and ddC during long-term combination therapy in patients with advanced infection with human immunodeficiency virus. J Acquir Immune Defic Syndr 1994; 7: 135-8
51. Gao WY, Agbaria R, Driscoll JS, et al. Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2′3′-dideoxynucleoside analogs in resting and activated human cells. J Biol Chem 1994; 269: 12633-8
52. Conway B, Ko DS, Marshall L, et al. Evaluation of ddC susceptibility in patients on AZT or ddI. 2nd International HIV Drug Resistance Workshop: 1993 Jun 3-5; Noordwijk
53. Kozal MJ, Kroodsma K, Winters MA, et al. Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy. Ann Intern Med 1994; 121: 263-8
54. Boyer PL, Tantillo C, Jacobo-Molina A, et al. Sensitivity of wild-type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleotides depends on template length; the sensitivity of drug-resistant mutants does not. Proc Natl Acad Sci USA 1994; 91: 4882-6
55. Gu Z, Gao Q, Fang H, et al. Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3′-dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1994; 38: 275-81
56. Fitzgibbon JE, Howell RM, Haberzettl CA, et al. Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2′,3′-dideoxycytidine. Antimicrob Agents Chemother 1992; 36: 153-7
57. Sylvester S, Caliendo A, An D, et al. HIV-1 resistance mutations and plasma RNA during ZDV and ddC combination therapy [abstract no. 47]. 4th International Workshop on HIV Drug Resistance: 1995 Jul 6-9; Sardinia
58. Moyle GJ. Influence of emergence of viral resistance on HIV treatment choice. Int J STD AIDS 1995; 6: 225-6
59. Moyle GJ. HIV treatment choice based on resistance patterns. Intervirology 1994; 37: 367-8
60. Eron JJ, Johnson VA, Merrill DP, et al. Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2′,3′-dideoxycytidine in vitro. Antimicrob Agents Chemother 1992; 36: 1559-62
61. Johnson VA, Merrill DP, Videler JA, et al. Two-drug combinations of zidovudine, didanosine, and recombinant interferon alpha inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. J Infect Dis 1991; 164: 646-55
62. Meng RC, Fischl MA, Boota AM, et al. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection: a phase I/II study. Ann Intern Med 1992; 116: 13-20
63. Collier AC, Coombes RW, Fischl MA, et al. Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. Ann Intern Med 1993; 119: 786-93
64. Harrigan PR, Kemp SD, Kinghorn I, et al. A placebo controlled trial of AZT alone or in combination with ddI or ddC: viral load and drug resistance. AIDS 1994; 8 Suppl. 4: S20
65. Shafer RW, Iversen AKN, Winters MA, et al. Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. J Infect Dis 1995; 172: 70-8
66. Fitzgibbon JE, Farnham AE, Sperber SJ, et al. Human immunodeficiency virus type 1 pol gene mutations in an AIDS patient treated with multiple antiretroviral drugs. J Virol 1993; 67: 7271-5
67. Larder BA, Kellam P, Kemp SD. Convergent combination therapy can select viable multidrug resistant HIV-1 in vitro. Nature 1993; 365: 451-3
68. Shafer RW, Kozal MJ, Winters MA, et al. Combination therapy with zidovudine and didanosine selects for drug resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J Infect Dis 1994; 169: 722-9
69. Shirasaka T, Kavlick MF, Veno T, et al. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci USA 1995; 92: 2398-402
70. Gao Q, Gu ZX, Parniak MA, et al. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1993; 37: 1390-2
71. Schinazi RF, Lloyd RJ, Nguyen M-H, et al. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother 1993; 37: 875-81
72. Wainberg MA, Salomon H, Gu Z, et al. Development of HIV-1 resistance to (-)2′-deoxy-3′-thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS 1995; 9: 351-7
73. Nijhuis M, de Jong D, van Leeuwen R, et al. The rise in HIV-1 RNA viral load during 3TC/AZT combination therapy is associated with the selection of viruses resistant to both 3TC and AZT [abstract no. 52]. 4th International Workshop on HIV Drug Resistance: 1995 Jul 6-9; Sardinia
74. Kuritzkes D, Shugarts D, Griffin A, et al. Resistance to lamivudine (3TC) and zidovudine (ZDV) in a phase II comparative trial of 3TC vs ZDV vs 3TC plus ZDV [abstract no. 53]. 4th International Workshop on HIV Drug Resistance: 1995 Jul 6-9; Sardinia
75. Harrigan PR, Bloor S, Kinghorn I, et al. Virological response to AZT/3TC combination therapy in AZT experienced patients (Trial NUCB3002) [abstract no. 54]. 4th International Workshop on HIV Drug Resistance: 1995 Jul 6-9; Sardinia
76. 3. 2nd National Congress on Human Retroviruses and Related Infections: 1995 Jan 29-Feb 2; Washington
77. Eron JJ, Benoit SL, Jemsek J, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med 1995; 333: 1662-9
78. 3. 2nd National Congress on Human Retroviruses and Related Infections: 1995 Jan 29-Feb 2; Washington
79. 3. 2nd National Congress on Human Retroviruses and Related Infections: 1995 Jan 29-Feb 2; Washington
80. Moyle G. Resistance to antiretroviral compounds: implications for the clinical management of HIV infection. Immunol Infect Dis 1995; 5: 170-82
81. Goulden MG, Cammack N, Hopewell PL, et al. Selection in vitro of an HIV-1 variant resistant to both lamivudine (3TC) and zidovudine. AIDS 1996; 10: 101-15
82. Kemp SD, Kohli A, Larder BA. Genotypic characterisation of an HIV-1 mutant co- resistant to AZT and 3TC [abstract no. 51]. 4th International Workshop on HIV Drug Resistance: 1995 Jul 6-9; Sardinia
83. 3) [abstract no. 55]. 4th International Workshop on HIV Drug Resistance: 1995 Jul 6-9; Sardinia
84. Gu Z, Gao Q, Li X, et al. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene encodes cross resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine. J Virol 1992; 66: 7128-35
85. Gu Z, Gao Q, Fang H, et al. Identification of novel mutations that conter drug resistance in the human immunodeficiency virus polymerase gene. Leukemia 1994; 8 Suppl. 1: 5166-9
86. Lacey SF, Larder BA. Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2′,3′didehydro-2′,3′-dideoxythymidine in cell culture. Antimicrob Agents Chemother 1994; 38: 1428-32
87. Mellors JW, Larder BA, Schinazi RF. Mutations in HIV-1 reverse transcriptase and protease associated with drug resistance. Int Antivir News 1995; 3: 8-12
88. Crowe S, McGrath MS, Elbeik T, et al. Chronically infected monocyte-macrophage (mø) are markedly less sensitive to zidovudine (AZT), Foscarnet (Fos) and alpha interferon (IFN) when compared to acutely infected mø. VIIth International Conference on AIDS: 1991 Jun 16-21; Florence
89. Barry M, Wild M, Veal G, et al. Zidovudine phosphorylation in HIV-infected patients and seronegative volunteers. AIDS 1994; 8: F1-5
90. Stretcher BN, Pesce J, Frame PT, et al. Correlates of zidovudine phosphorylation with markers of HIV disease progression and drug toxicity. AIDS 1994; 8: 763-9
91. Dianzani F, Antonelli G, Turriziani O, et al. Zidovudine induces the expression of cellular resistance affecting its antiviral activity. AIDS Res Hum Retroviruses 1994; 10: 1471-8
92. Back DJ, Haggard PG, Veal GJ, et al. Intracellular phosphorylation interactions between nucleoside analogues [abstract no. 41]. 5th European Conference on Clinical Aspects and Treatment of HIV Infection: 1995 Sep 26-29; Copenhagen
93. Kohl NE, Emini EA, Schleif WA. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA 1988; 85: 4686-90
94. Kempf DJ, Marsh KC, Paul DA, et al. Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother 1991; 35: 2209-14
95. Eberle J, Bechowsky B, Rose D, et al. Resistance of HIV type I to proteinase inhibitor RO31-8959. AIDS Res Hum Retroviruses 1995; 11: 671-6
96. Vella S, Butto S, Franco M, et al. Viral load and CD4+ responses during combination therapy with zidovudine and saquinavir: correlation with emergence of viral isolates with reduced sensitivity [abstract no. 43]. 4th International Workshop on HIV Drug Resistance: 1995 Jul 6-9; Sardinia
97. Jacobsen H, Yasargil K, Winslow DL, et al. Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro31-8959. Virology 1995; 206: 527-34
98. Jacobsen H, Haenggi M, Ott M, et al. Reduced sensitivity of saquinavir: an update on genotyping from phase I/II trials [abstract no. 68]. 4th International Workshop on HIV Drug Resistance: 1995 Jul 6-9; Sardinia
99. Jacobsen H Haenggi M, Ott M, Duncan I, et al. Resistance to saquinavir: update of the genotypic analysis of phase II trials [abstract no. 1174]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1995 Sep 17-20; San Francisco (CA)
100. Wilson SI, Phylip LH, Mills JS, et al. Interactions of substrates and inhibitors with escape mutants of HIV-1 proteinase [abstract no. 66]. 4th International Workshop on HIV Drug Resistance: 1995 Jul 6-9; Sardinia
101. Schapiro JM, Winters MA, Kozal MJ, et al. Saquinavir monotherapy trial: prolonged suppression of viral load and resistance mutations at higher dosage [abstract no. LB-5]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1995 Sep 17-20; San Francisco
102. El-Farrash MA, Kuroda MJ, Kitazaki T, et al. Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protense inhibitor. J Virol 1994; 68: 233-9
103. Ho DD, Toyoshima T, Mo H, et al. Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C-2 symmetric protease inhibitor. J Virol 1994; 68: 2016-20
104. Mellors JW, McMahon DK, Chodakewitz JA, et al. Correlation between genotypic evidence of HIV-1 resistance to the protease inhibitor MK-639 and loss of antiviral effect in treated patients [abstract no. 71]. 4th International Workshop on HIV Drug Resistance: 1995 Jul 6-9; Sardinia
105. Merck & Co., Inc. Indinavir (Crixivan®) Data Sheet. West Point (PA), USA
106. Abbott. Ritonavir (Norvir®) Data Sheet. Abbott Park (IL), USA
107. Molla A, Boucher CAB, Korneyeva M, et al. Evolution of resistance to the protease inhibitor ritonavir (ABT-538) in HIV infected patients [abstract no. 69]. 4th International HIV Drug Resistance Workshop: 1995 Jul 6-9; Sardinia
108. Patick AK, Mo H, Markowitz M, et al. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob Agents Chemother 1996; 40: 292-7
109. Patick A, Mo H, Markowitz M, et al. In vitro antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of HIV-1 protease [abstract no. 184]. 2nd National Conference on Human Retroviruses and Related Infections: 1995 Jan 29-Feb 2: Washington
110. Kim EE, Dwyer MD, Thompson JA, et al. Structural analysis of the basis of viral resistance to VX-478 [abstract no. 1278]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1995 Sep 17-20; San Francisco
111. Tisdale M, Myers RE, Blair E, et al. In vitro studies support combination therapy with HIV protease inhibitors [abstract no. 61]. 4th International HIV Drug Resistance Workshop: 1995 Jul A-9; Sardinia
112. Winslow DL, Stack S, King R, et al. Limited sequence diversity of the HIV type-1 protease gene from clinical isolates and in vitro susceptibility to HIV protease inhibitors. AIDS Res Hum Retroviruses 1995; 11: 107-13
113. Kageyama S, Anderson BD, Hoestery BL, et al. Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteins. Antimicrob Agents Chemother 1994; 38: 1107-11
114. 1 acid glycoprotein. J Infect Dis 1995; 171: 546-51
115. Fischl MA, Richman DD, Flexner C, et al. Phase 1 study of two formulations and dose schedules of SC-52151, a protease inhibitor [abstract no. 186]. 2nd National Conference on Human Retroviruses and Related Infections: 1995 Jan 29-Feb 2; Washington
116. Kohlstaedt LA, Wang J, Friedman JM, et al. Crystal structure at 3.5Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992; 256: 1783-90
117. D'Aquilla RT. HIV-1 drug resistance: molecular pathogenesis and laboratory monitoring. Clin Lab Med 1994; 14: 393-423
118. Arnold E, Ding J, Hughes SH, et al. Structures of DNA and RNA polymerases and their interactions with nucleic acid substrates. Curr Opin Struct Biol 1995; 5: 27-38
119. Richman DD, Havlir D, Corbeil J. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994; 68: 1660-6
120. Richman DD, Shih C-K, Lowy I, et al. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sci USA 1991; 88: 11241-5
121. Balzarini J, Karlsson A, Pérez-Pérez M-J, et al. Human immunodeficiency virus type 1-specific [2′,5′-bis-O-(tert-butyl-dimethylsilyl)-b-D-ribofuranosyl]-3′- spiro-5″-(4″-ammo-1′, 2″-oxathiole-2′2″-dioxide) purine analogs show a resistance spectrum that is different from that of the human immunodeficiency virus type 1 specific non-nucleoside analogues. Mol Pharmacol 1993; 43: 109-14
122. Karlsson A, Balzarini, J Pérez-Pérez MJ, et al. Human immunodeficiency virus type 1 (HIV-1) strains emerging after drug therapy [abstract no. 24]. 2nd International HIV Drug Resistance Workshop: 1993 Jun 3-5; Noordwijk
123. Staszewski S, Miller V, Kober A, et al. Evaluation of teh efficacy and tolerance of R 018893, R 089439 (loviride) and placebo in asymptomatic HIV-1-infected patients. Antiviral Ther 1996; 1: 42-50
124. Staszewski S, Miller V, Rehmet S, et al. Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1 infected patients. AIDS 1996; 10: F1-7
125. Balzarini J, Karlsson A, Pérez-Pérez M-J, et al. HIV-1 specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase. Virology 1992; 192: 246-53
126. Dueweke TJ, Pushkarskaya T, Poppe SM, et al. A mutation in reverse transcriptase of his [heteroaryl] piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. Proc Natl Acad Sci USA 1993; 90: 4713-7
127. Demeter L, Resnick L, Nawaz T, et al. Phenotypic and genotypic analysis of atevirdine (ATV) susceptibility of HIV-1 isolates obtained from patients receiving ATV monotherapy in a phase 1 clinical trial (ACTG 187): comparison to patients receiving combination therapy with ATV and zidovudine. 3rd Workshop on Viral Resistance: 1493; Gaithersburg
128. Kleim J-P, Rösner M, Winkler I, et al. Nucleoside RT inhibitor specific mutations within the HIV-1 pol gene selected with a non-nucleoside type RT inhibitor [abstract]. J Acquir Immune Defic Syndr 1995; 10 Suppl. 3: 2
129. D'Aquila R, Hughes M, Liou S-H, et al. A comparative study of a combination of zidovudine, didanosine and double-blinded nevirapine versus a combination of zidovudine and didanosine [abstract no. 384]. 2nd National Conference on Human Retroviruses and Related Infections: 1995 Jan 29-Feb 2; Washington
130. Staszewski S, Massari FE, Kober A, et al. Combination therapy wild zidovudine prevents selection of human immunodeficiency virus type 1 variants expressing high-level resistance to L697,661, a non-nucleoside reverse transcriptase inhibitor. J Infect Dis 1995; 171: 1159-65
131. Nunberg JH, Schleif WA, Boots EJ, et al. Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J Virol 1990; 65: 4887-92
132. DeJong MD, Loewenthl M, Boucher CAB, et al. Alternating nevirapine and zidovudine treatment of human immunodeficiency virus type 1 infected persons does not prolong nevirapine activity. J Infect Dis 1994; 169: 1346-50
133. Cheeseman SH, Havlir D, McLaughin MM, et al. Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J Acquir Immune Defic Syndr 1995; 8: 141-51
134. Goldman ME, O'Brien JA, Ruffing TL, et al. A nonnucleoside reverse transcriptase inhibitor active on human immunodeficiency virus type 1 isolates resistant to related inhibitors. Antimicrob Agents Chemother 1993; 37: 947-9
135. St Clair MH, Hartigan PM, Andrews JC et al. Zidovudine resistance, syncytium-inducing phenotype and HIV disease progression in a case control study. J Acquir Immune Defic Syndr 1993; 6: 891-7
136. Wildemann B, Haas J, Ehrhart K, et al. In vivo comparison of zidovudine resistance mutations in blood and CSF of HIV-1 infected patients both simultaneously in plasma but also between different body compartments such as blood and CSF. Neurology 1993; 43: 2659-63
137. Delassus S, Cheynier R, Wain-Hobson S. Nonhomogeneous distribution of human immunodeficiency virus type 1 proviruses within the spleen. J Virol 1992; 66: 5642-5
138. Korber BTM, Kunstman KJ, Patterson BK, et al. Genetic differences between blood- and brain-derived viral sequences from human immunodeficiency virus type 1-infected patients: evidence of conserved elements in the V3 region of the envelope protein of brain-derived sequences. J Virol 1994; 68: 7467-81
139. Ball JK, Holmes EC, Whitwell H, et al. Genomic variation of human immunodeficiency virus type 1 (HIV-1): molecular analyses of HIV-1 in sequential blood samples and various organs obtained at autopsy. J Gen Virol 1994; 75: 867-79
140. Portegies P. HIV-1, the brain, and combination therapy. Lancet 1995; 346: 1244-5
141. Di Stefano M, Norkans G, Chiodi F, et al. Zidovudine-resistant variants of HIV-1 in brain. Lancet 1993; 342: 865
142. Gazzard BG, Moyle GJ. Individualisation of HIV therapy: the clinician's perspective. Br J Clin Prac 1995; 49: 145-7
143. Kozal MJ, Shafer RW, Winters MA, et al. A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. J Infect Dis 1993; 167: 526-32
144. Ogino MT, Danker WM, Spector SA. Development and significance of zidovudine resistance in children infected with human immunodeficiency virus. J Pediatr 1993; 123: 1-8
145. Loveday C, Kaye S, Tenant-Flowers M, et al. HIV-1 RNA serum-load and resistant viral genotypes during early zidovudine therapy. Lancet 1995; 345: 820-4
146. Cinatl Jr J, Cinatl J, Rabenau H, et al. Failure of antiretroviral therapy: role of viral and cellular factors. Intervirology 1994; 37: 307-14
147. Saag MS, Emini EA, Laskin OL, et al. A short term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase: L-697,661 working group. N Engl J Med 1993; 329: 1065-72
148. Tudor-Williams G, St Clair MH, McKinney RE, et al. HIV-1 sensitivity to zidovudine and clinical outcome in children. Lancet 1992; 339: 15-9
149. Montaner JSG, Singer J, Schechter MR, et al. Clinical correlates of in vitro HIV-1 resistance to zidovudine: results of the multicenter Canadian AZT trial. AIDS 1993; 7: 189-96
150. Principi N, Marchisio P, Pasquale M, et al. HIV-1 reverse transcriptase codon 215 mutation and clinical outcome in children treated with zidovudine. AIDS Res Hum Retroviruses 1994; 19: 721-6
151. D'Aquila RT, Johnson VA, Welles SL, et al. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Intern Med 1995; 122: 401-8
152. Tremblay M, Rooke R, Wainberg MA. Zidovudine-resistant and -sensitive HIV-1 isolates from patients on drug therapy: in vitro studies evaluating level of replication- competent viruses and cytopathogenicity. AIDS 1992; 6: 1445-9
153. Caliendo A, Savara A, An D, et al. ZDV resistance mutations increase replication in drug-free PBMC stimulated after infection [abstract no. 4]. 4th International Workshop on HIV Drug Resistance: 1995 Jul 6-9; Sardinia
154. Holodniy M, Eastman S, Mole L, et al. Reduction of plasma HIV viral load during ddl/ZDV combination therapy in the presence of ZDV resistance [abstract no. 9]. 1st National Conference on Human Retroviruses and Related Infections: 1993 Dec 12-16; Washington
155. Moyle G, Gazzard B. Current knowledge and future prospects for the use of HIV protease inhibitors. Drugs 1996 May; 51 (5): 701-12
156. Perrin L, Yerly S, Rakik A, et al. Transmission of 215 mutants in primary HIV infection and analysis after 6 months of ZDV [abstract no. 21]. 4th International Workshop on HIV Drug Resistance: 1995 Jul 6-9; Sardinia
157. Harzic M, Patey O, Ferchal F, et al. AZT resistance mutations in virus
158. Kojima E, Shirasaka T, Anderson BD, et al. Human immunodeficiency virus type 1 (HIV-1) viraemia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine or didanosine therapy. J Infect Dis 1995; 171: 1152-8
159. Havlir D, Cheeseman SH, McLaughlin M, et al. High dose nevirapine: safety, pharmacokinetics and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995; 171: 537-45